TP53 and acute myeloid leukemia: A Phase 1 trial has been started for AMG176 in relapsed/refractory AML or multiple myeloma (NCT02675452) and DT2216 in various relapsed malignancies (NCT04886622), respectively, though these trials do not specify for participants to have TP53 mutations.